Melinta Therapeutics (MLNT) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free MLNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSWTX SpringWorks Therapeutics, Inc.seekingalpha.com - April 23 at 8:32 AMFDA Requests Additional Data for Venatorx and Melinta's Antibiotic Combinationmsn.com - February 28 at 3:41 PMPromising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIsmsn.com - February 27 at 7:43 AMVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactamfinance.yahoo.com - February 23 at 2:00 PMCidara, Melinta announce publication of Rezzayo data in medical journalmsn.com - December 5 at 2:56 PMMelinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.finance.yahoo.com - November 9 at 2:53 PMMelinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023finance.yahoo.com - October 11 at 12:19 PMMelinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)uk.finance.yahoo.com - October 2 at 8:24 PMMelinta Therapeutics, Inc.thestreet.com - September 26 at 10:09 PMMelinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canadafinance.yahoo.com - May 15 at 9:02 AMCidara Therapeutics Sheds Skin, Shifts To Immunotherapyseekingalpha.com - March 1 at 11:05 AMBiVictriX Therapeutics reports "really exciting" BCX001 datafinance.yahoo.com - February 24 at 10:21 PMOptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired Eventtechnews.tmcnet.com - October 20 at 10:19 AMMelinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.finance.yahoo.com - July 27 at 9:38 AMMelinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Developmentfinance.yahoo.com - October 25 at 9:58 AMMelinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)apnews.com - September 20 at 8:19 AM Get Melinta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.) Get the free details now. MLNT Media Mentions By Week MLNT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLNT News Sentiment▼0.000.44▲Average Medical News Sentiment MLNT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLNT Articles This Week▼10▲MLNT Articles Average Week Get Melinta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CPIX News Today ADIL News Today CVKD News Today PTIX News Today TENX News Today CLVR News Today TRVN News Today CANF News Today EFTR News Today ENVB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLNT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
